Keywords: Vectura, Novartis, NVA237, QVA149, Research, Respiratory

Vectura gives positive update on NVA237, but see delays for QVA149 milestone

Article | 22 October 2009

Print This

There was good and some disappointing news from UK inhaled drug developer Vectura, which announced that the Phase III trials ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in